Breaking: UBS Maintains $15 Price Target On Sucampo Pharmaceuticals (NASDAQ:SCMP) Shares, Maintains Their Original Buy Rating

October 13, 2017 - By Adrian Mccoy

 Breaking: UBS Maintains $15 Price Target On Sucampo Pharmaceuticals (NASDAQ:SCMP) Shares, Maintains Their Original Buy Rating

Investors sentiment decreased to 1.33 in Q2 2017. Its down 0.06, from 1.39 in 2017Q1. It dropped, as 23 investors sold Sucampo Pharmaceuticals, Inc. shares while 40 reduced holdings. 25 funds opened positions while 59 raised stakes. 24.71 million shares or 3.79% less from 25.68 million shares in 2017Q1 were reported.

13,608 were reported by Nationwide Fund Advsrs. Renaissance Technologies Limited Liability Co holds 0.01% or 810,600 shares in its portfolio. Advisory Networks Ltd Llc owns 0% invested in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) for 195 shares. Alphamark Advisors Limited Liability Corp invested in 98,400 shares. Ameritas Investment Prtnrs holds 0% of its portfolio in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) for 1,939 shares. Moreover, Bowling Management Limited Liability Com has 0.21% invested in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP). Virginia Retirement Et Al owns 56,900 shares. Affinity Lc has invested 0.03% in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP). Alliancebernstein L P has 38,362 shares for 0% of their portfolio. Citigroup owns 339,269 shares or 0% of their US portfolio. California Public Employees Retirement System has 0% invested in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) for 11,800 shares. Stevens Management Limited Partnership holds 0.02% or 60,467 shares in its portfolio. Herndon Cap Mngmt Ltd Co, a Georgia-based fund reported 458 shares. Panagora Asset Inc reported 120,005 shares. Grp Inc holds 0% or 18,215 shares in its portfolio.

Sucampo Pharmaceuticals (NASDAQ:SCMP) Rating Reaffirmed

In a research report issued to clients and investors this morning, UBS reiterated their Buy rating on Sucampo Pharmaceuticals (NASDAQ:SCMP) shares. The PT would suggest a possible upside of 47.78 % from company’s close price.

Investors sentiment decreased to 1.33 in Q2 2017. Its down 0.06, from 1.39 in 2017Q1. It dropped, as 23 investors sold Sucampo Pharmaceuticals, Inc. shares while 40 reduced holdings. 25 funds opened positions while 59 raised stakes. 24.71 million shares or 3.79% less from 25.68 million shares in 2017Q1 were reported.

13,608 were reported by Nationwide Fund Advsrs. Renaissance Technologies Limited Liability Co holds 0.01% or 810,600 shares in its portfolio. Advisory Networks Ltd Llc owns 0% invested in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) for 195 shares. Alphamark Advisors Limited Liability Corp invested in 98,400 shares. Ameritas Investment Prtnrs holds 0% of its portfolio in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) for 1,939 shares. Moreover, Bowling Management Limited Liability Com has 0.21% invested in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP). Virginia Retirement Et Al owns 56,900 shares. Affinity Lc has invested 0.03% in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP). Alliancebernstein L P has 38,362 shares for 0% of their portfolio. Citigroup owns 339,269 shares or 0% of their US portfolio. California Public Employees Retirement System has 0% invested in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) for 11,800 shares. Stevens Management Limited Partnership holds 0.02% or 60,467 shares in its portfolio. Herndon Cap Mngmt Ltd Co, a Georgia-based fund reported 458 shares. Panagora Asset Inc reported 120,005 shares. Grp Inc holds 0% or 18,215 shares in its portfolio.

Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) Ratings Coverage

Among 9 analysts covering Sucampo Pharma (NASDAQ:SCMP), 6 have Buy rating, 0 Sell and 3 Hold. Therefore 67% are positive. Sucampo Pharma has $31 highest and $11.0 lowest target. $21.33’s average target is 110.15% above currents $10.15 stock price. Sucampo Pharma had 31 analyst reports since August 6, 2015 according to SRatingsIntel. The stock of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) has “Buy” rating given on Wednesday, April 20 by Mizuho. The firm earned “Buy” rating on Tuesday, November 15 by Maxim Group. Jefferies maintained Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) rating on Wednesday, March 9. Jefferies has “Hold” rating and $16 target. On Tuesday, February 9 the stock rating was initiated by UBS with “Buy”. The stock of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) earned “Neutral” rating by Mizuho on Monday, January 18. The company was upgraded on Thursday, December 22 by Mizuho. The company was downgraded on Thursday, August 4 by Mizuho. The firm earned “Buy” rating on Wednesday, August 2 by Maxim Group. TH Capital reinitiated the shares of SCMP in report on Thursday, October 29 with “Buy” rating. The firm has “Mkt Perform” rating given on Thursday, September 3 by Leerink Swann.

About 513,583 shares traded. Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) has declined 5.30% since October 13, 2016 and is downtrending. It has underperformed by 22.00% the S&P500.

Analysts expect Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) to report $0.25 EPS on November, 8.They anticipate $0.03 EPS change or 10.71 % from last quarter’s $0.28 EPS. SCMP’s profit would be $11.70 million giving it 10.15 P/E if the $0.25 EPS is correct. After having $0.28 EPS previously, Sucampo Pharmaceuticals, Inc.’s analysts see -10.71 % EPS growth.

Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company. The company has market cap of $474.84 million. The Firm is focused on the development and commercialization of pharmaceutical products. It currently has negative earnings. The Company’s primary focus areas are gastroenterology, ophthalmology and oncology-related disorders.

More recent Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) news were published by: Bizjournals.com which released: “Md. biotech expands HQ in ramp-up for potential drug approval” on September 19, 2017. Also Globenewswire.com published the news titled: “Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 2017 …” on September 19, 2017. Seekingalpha.com‘s news article titled: “Sucampo Firing Sales Torpedos” with publication date: September 07, 2017 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.